Correlation between Ki67 and Breast Cancer Prognosis

Kontzoglou, Konstantinos; Palla, Victoria; Karaolanis, Georgios; Karaiskos, Ioannis; Alexiou, Ioannis; Pateras, Ioannis S.; Konstantoudakis, Konstantinos; Stamatakos, Michael

doi:10.1159/000346475

Cited by 117 publications

(94 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present population-based study revealed that Ki67 was significantly associated with all the clinicopathological parameters, with the exception of age. In accordance with previous studies, the present study confirmed the importance of the Ki67 level in predicting the prognosis of BC (23)(24)(25)(26).…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population‑based study

et al. 2015

View full text Add to dashboard Cite

Abstract. Ki67 has potential prognostic and predictive values for breast cancer patients, and has become an important biomarker in routine clinical practice. The aims of the present study were to investigate the distribution of Ki67 expression and its correlation with other clinicopathological parameters in central China. In total, 1,259 patients with newly-diagnosed invasive breast cancer were included in the present study. The clinical information was obtained from the electronic medical records. The expression levels of Ki67, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) were detected by immunohistochemical analysis. The associations between Ki67 scores and other prognostic factors were evaluated as continuous and categorical variables. The mean value of the Ki67 scores of all patients was 31%. In total, ~36% (456/1,259) of the patients demonstrated a low expression of Ki67. A statistically significant correlation was identified between the mean Ki67 scores and the lymph node status, tumor grade, ER, PR and HER2 status, and clinical stage or molecular subtypes (all P<0.001). When Ki67 was categorized into high (>14%) and low (≤14%) level groups, the χ 2 test was used to verify these results. The Ki67 scores demonstrated no statistically significant differences between the HER2-positive (non-luminal) and three negative subtypes, with the exception of patients with a tumor size of >2 cm (P=0.02). In conclusion, the results revealed the presence of significant correlations between Ki67 and other clinicopathological parameters.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Ki67 is a proliferation marker that is expressed in all the phases of the cell cycle, with the exception of the G 0 phase (2)(3)(4). A number of studies have demonstrated the prognostic value of Ki67 in BC (5,6). In addition, Ki67 levels are useful in identifying patients that are most likely to benefit from chemotherapy (7).…”

Section: Introductionmentioning

confidence: 99%

Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population‑based study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…ER status has been largely identified as being inversely correlated with Ki-67, with the higher rates of ER positivity shown in the lowest proliferating tumors 21 . Moreover, it could be demonstrated that high levels of Ki-67 are associated with HER2/-neu positivity according to former studies.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Ki-67 in Breast Cancer

Velappan¹,

Shunmugam²

2017

IOSR JDMS

View full text Add to dashboard Cite

“…Many studies have demonstrated the primary role of proliferation signatures in breast cancer and most of them support the prognostic value of Ki67. 5,6 For example, a gene expression-based intrinsic subtype classification of breast cancers with pathological features found that a Ki67 score $14% distinguished luminal B from luminal A. 7 This was subsequently supported by the…”

Section: Introductionmentioning

confidence: 91%

Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer

Sun¹,

Chen²,

Jiang³

et al. 2014

IJN

View full text Add to dashboard Cite

Background The immunohistochemical assessment of Ki67 antigen (Ki67) is the most widely practiced measurement of breast cancer cell proliferation; however, it has some disadvantages and thus the prognostic value of Ki67 in breast cancer remains controversial. Our previous studies confirmed the advantages of quantum dots-based nanotechnology for quantitative analysis of biomarkers compared with conventional immunohistochemistry (IHC). This study was designed to assess Ki67 by quantum dot-immunohistochemistry (QD-IHC) and investigate the prognostic value of the Ki67 score in human epidermal growth factor receptor 2 (HER2)-positive (non-luminal) breast cancer. Methods Ki67 expression in 108 HER2-positive (non-luminal) breast cancer specimens was detected by IHC and QD-IHC. Two observers assessed the Ki67 score independently and comparisons between the two methods were made. The prognostic value of the Ki67 score for five-year disease-free survival was estimated. Results The same antigen localization, high correlation of staining rates ( r =0.993), and high agreement of measurements (κ=0.874) of Ki67 expression (cutoff: 30%) in breast cancer were found by QD-IHC and conventional IHC. The QD-IHC had a better interobserver agreement for the Ki67 score than conventional IHC ( t =−7.280, P <0.01). High Ki67 expression (cutoff: 30%) was associated with shorter disease-free survival (log-rank test; IHC, P =0.026; QD-IHC, P =0.001), especially in the lymph node-negative subgroups (log-rank test; IHC, P =0.017; QD-IHC, P =0.002). Conclusion QD-IHC imaging of Ki67 was an easier and more accurate method for detecting and assessing Ki67. The Ki67 score was an independent prognosticator in the HER2-positive (non-luminal) breast cancer patients.

show abstract

Correlation between Ki67 and Breast Cancer Prognosis

Cited by 117 publications

References 136 publications

Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population‑based study

Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population‑based study

Evaluation of Ki-67 in Breast Cancer

Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer

Contact Info

Product

Resources

About